कंपनी का अवलोकन
Scholar Rock Holding Corporation is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for patients suffering from spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular disorders. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on research and development to bring novel molecular mechanisms to market. This organization employs a workforce of 289 individuals, reflecting a mid-sized operational scale typical for specialized biotech firms. With a market capitalization of $5.74B, the company holds a substantial valuation relative to its current financial output, indicating that the market assigns a high value to its pipeline potential despite the absence of reported annual revenue figures in recent filings.
वित्तीय स्वास्थ्य
The financial statements for Scholar Rock Holding Corporation reveal a net income of $-377,939,008 and an EBITDA of $-382,987,008 for the trailing twelve months, while revenue data is not currently available for public reporting. The significant gap between the non-existent or unreported revenue and the substantial net loss highlights a cost structure dominated by high fixed expenses, such as clinical trial costs and research personnel, which are characteristic of early-stage development phases. The company generated a free cash flow of $-162,622,256, which signifies a heavy consumption of cash reserves to fund operations and development activities rather than generating liquidity. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that these figures are not materialized in the current reporting period. On the balance sheet, the company holds $367.56M in cash against $108.92M in debt, resulting in a debt-to-equity ratio of 44.37, which suggests a leveraged position where liabilities are nearly half the size of shareholder equity. Despite the debt, the current ratio stands at 6.95, demonstrating a robust short-term liquidity position that allows the firm to comfortably meet its immediate obligations. Furthermore, the return on equity is -123.1% and the return on assets is -54.7%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and creditors due to the company's ongoing developmental stage.
मूल्यांकन आकलन
The valuation metrics for Scholar Rock Holding Corporation show a trailing P/E ratio listed as N/A and a forward P/E of -23.30, implying that expected earnings are currently negative and thus traditional price-to-earnings valuation models are not applicable at this time. The price-to-book ratio is reported at 22.09, which indicates that the market is valuing the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and drug pipeline. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A, while the EV/EBITDA stands at -14.32, suggesting that the enterprise value is being priced relative to negative earnings, a common scenario for unprofitable biotech firms. The stock has traded within a 52-week range with a high of $51.62 and a low of $22.71, meaning the current market price sits somewhere within this historical volatility band. The beta value is 0.69, indicating that the stock's price volatility is lower than the broader market, suggesting it is less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Regarding growth metrics, the revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data available to compare the pace of earnings expansion against revenue generation. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which implies that the organization retains all its available earnings to reinvest into research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies that prioritize long-term pipeline growth over immediate income distribution to investors. Consequently, the overall growth and income profile of Scholar Rock Holding Corporation is characterized by a complete lack of current income generation and undefined growth rates, relying entirely on future clinical successes and regulatory approvals to shift the financial trajectory from the current negative earnings state.